Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp

AstraZeneca PLC (NASDAQ:AZN) is one of the most profitable blue chip stocks to invest in now. Guggenheim lifted the price target on AstraZeneca PLC (NASDAQ:AZN) to 16,000 GBp from 15,500 GBp on March 10, reiterating a Buy rating on the shares and telling investors that it is updating its model after the company’s fiscal 2025 results and follow-up presentations at several investor conferences.

AstraZeneca’s (AZN) Dividend: Resilient, Predictable, and Built on Innovation

The rating update came after the company announced on March 9 that AstraZeneca PLC (NASDAQ:AZN) and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu has been accepted and granted Priority Review in the US by the Food and Drug Administration (FDA) for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.

It reported that the FDA grants Priority Review to applications for medicines that, upon their approval, have the potential to offer considerable improvements over the available treatment options by exhibiting safety or efficacy improvements, boosting patient compliance, or preventing serious conditions. AstraZeneca PLC (NASDAQ:AZN) stated that the Prescription Drug User Fee Act date, the FDA action date for its regulatory decision, is expected during the third quarter of 2026.

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians, and is involved in exploring novel immuno-oncology treatment approaches. AstraZeneca PLC (NASDAQ:AZN) distributes its products and services through local representative offices and distributors.

While we acknowledge the risk and potential of AZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AZN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.